A B S T R A C T To explore the possibility that the behavior of immune complexes can, under some circumstances, be directed by the antigen, we have studied the behavior of complexes of identical size made with the glycoproteins, orosomucoid (OR), and ceruloplasmin; or with their desialylated derivatives, asialo-orosomucoid (ASOR) and asialo-ceruloplasmin. Such desialylated proteins are rapidly removed from the circulation by a hepatic cell receptor for galactose, the sugar exposed upon removal of sialic acid.
plexes were cleared more rapidly than light OR complexes but not so rapidly as heavy ASOR complexes. The clearance and hepatic uptake of the heavy OR complexes were markedly suppressed by a prior injection of heat-aggregated gamma globulin, a known Fc receptor-blocking agent (45% hepatic uptake without and 6% with aggregated gamma globulin). The heavy rabbit ASOR complexes exhibited inhibition of blood clearance and hepatic uptake by both galactose receptor-blocking and Fc receptor-blocking agents. A blocking dose of ASOR reduced the hepatic uptake at 30 min from 75 to 49%, and heat-aggregated gamma globulin reduced it from 75 to 39%, which suggests that these heavy complexes were removed from the circulation by receptors both for the immunoglobulin and for the antigen. Cell separation studies and autoradiographs confirmed that those complexes cleared primarily by galactose-mediated mechanism were within hepatocytes, and those cleared by Fc receptors were within the nonparenchymal cells of the liver. It seems probable, therefore, that some antigen-antibody complexes may be removed from the circulation via receptors not only for immunoglobulin but also for antigen. INTRODUCTION Immunoglobulins are a set of heterogenous molecules which, upon reacting with antigen, can transmit common effector messages to complement, to macrophages, to lymphocytes, and to other cells. Antigen initiates this process by binding to the Fab regions of immunoglobulin molecules, which results in a multimolecular complex with grouped Fc pieces. Although the Fc pieces have no specificity for the antigen and appear to remain largely or entirely unaltered afier antigen binding, all further reactions of the complex have been considered to involve interaction of the grouped Fc pieces with cellular receptors or serum proteins (1) . In this view, antigens merely aggregate Fe pieces, thereby allowing effector systems to distinguish the aggregated Fc pieces of the immune complex from the monomer Fc pieces of uncomplexed immunoglobulins. Since the effector systems can also recognize Fc pieces aggregated without antigen, e.g., by heat or chemical aggregation (2) , such a view seems adequately to explain the normal or ideal operation of the humoral immune system.
There has been considerable study of those properties of immune complexes and of the effector systems that might allow complexes to circulate abnormally and deposit at abnormal sites (3) (4) (5) . The size of complexes certainly influences the length of their survival in the circulation (6) , their ability to fix complement (7) , and the affinity of their binding to reticuloendothelial Fc receptors (8) . The class or subclass of antibody also affects those properties (9) . A failure of Fc or complement receptor function might lead to prolonged survival of complexes, as might a depletion of certain complement components.
But the size, immunoglobulin class, and complement-fixing ability of complexes do not by themselves seem able to account for the great variety of tissue localizations and subsequent reactions that have been ascribed to immune complexes. It is not clear why, for example, some complexes deposit in the glomerular basement membrane and others do not. It is possible that antigen may deposit first in a tissue and that antibody follows (10) . The interaction of DNA within glomerular or epidermal basement membranes, for example, may direct antibody to those sites (11) . In addition, the charge-selective properties of the glomerulus influence which molecules pass freely and which are retained (12) . This anionic membrane may also be important in regulating the pattern of immune complex deposition within the glomeruli (13 (18) , and derivitizing it with galactose using cyanomethyl-1-thio-,3-n-galactopyranoside (Sigma Chemical Co.), as described by Lee (19) . (Full publication of the method is in preparation.) Antibody preparation and isolation. Goat serum containing antibodies raised against ASOR was a kind gift of Dr. J. Robbins, Bureau of Biologics, National Institutes of Health, Bethesda, Md. To obtain rabbit antibodies outbred New Zealand white rabbits were injected at multiple subcutaneous and intramuscular sites with 3 mg OR or ceruloplasmin emulsified in complete Freund's adjuvant and, 3 wk later, with the same amount emulsified in incomplete Freund's adjuvant. 6 wk later, when the sera contained 0.7-0.9 mg/ml of anti-OR antibodies or 3-4 mg/ml of anticeruloplasmin antibodies, as determined by precipitin test, animals were exsanguinated. Although all the experiments reported here were carried out on sera obtained from single rabbits, we have found similar results with sera from other rabbits. The rabbit sera were heated to 56°C for 30 min before antibody purification. The antibodies were purified by passing the serum over OR or ceruloplasmin affinity columns, prepared as described (20) . For anti-OR antibodies, 15 ml of anti-OR antiserum was applied to a 0.7 x 6.5-cm OR-Sepharose 4B column equilibrated with 0.02 M Tris, pH 7.8,0.15 M NaCl. After extensive washing with the same buffer, antibodies were eluted with 0.15 M NaCl, 0.20 M acetic acid; fractions of 1 ml were collected into tubes containing 0.25 ml of 1 M sodium acetate, pH 5.3. For anticeruloplasmin antibodies a ceruloplasmin affinity column was used, elution was with 1 M acetic acid, and the pooled protein-containing fractions were neutralized with dilute NaOH. The eluted antibodies were dialyzed against borate-buffered saline.
Mouse IgG antidinitrophenyl model immune complexes were prepared with the bis-affinity labeling reagent, bis-2, 4-dinitrophenyl pimelic ester, as described (21) .
Radioiodination of antibody and antigen. Antibodies were radiolabeled with carrier-free Na125I (New England Nuclear, Boston, Mass) with a modified iodine monochloride method at 1 mCi/mg protein, as previously described (22) . Antigens were radiolabeled with carrier-free Na131I with either the modified iodine monochloride method at 1 mCi/mg or chloramine-T (23) at 5 mCi/mg protein.
Preparation of immune complexes. Soluble immune complexes were prepared by adding antigen to a solution of purified antibodies and separating unreacted antibodies and antigens from complexes by density gradient centrifugation. In a series of preliminary experiments, trial sucrose gradients of antigen-antibody mixtures with different ratios (all in the region of antigen excess as determined by a precipitin test) were done to find the ratio yielding the largest amount of heavy soluble complexes. For the goat antibody this was achieved by adding eightfold more antigen than equivalence. For the rabbit antibody, 1.75-fold more antigen than equivalence was optimal. In all cases the native and desialylated antigens behaved identically with respect to the formation of soluble complexes.
To prepare complexes for injection, 20 ,mg of 125I-antibody was combined with either 12.4 ug of nonradioactive or 131I_ antigen (goat antibodies) or 3.1 ug of antigen (rabbit antibodies) in a final volume of 200 ,ul. After incubation at room temperature for 30-60 min, the mixture was layered on top of a 4.8-ml 10-30% linear sucrose gradient in 0.15 M NaCl-0.01 M sodium phosphate, pH 7.4. Gradients were placed in a Beckman SW50.1 rotor and centrifuged at 40,000 rpm for 13-14 h in a Beckman model 65LB centrifuge at 0°C (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.). The bottom of the tube was punctured and fractions containing three drops each were obtained. Generally there were 28 fractions per gradient. Fig. 1 shows a typical gradient pattern for the goat and rabbit antibodies. Identical gradient patterns were obtained with OR and ASOR. Similar sucrose gradients of antibody alone or in complexes with antibody excess showed that there was no self-aggregation of the IgG molecules.
Of the goat complexes the first 11 fractions were pooled and injected without further handling. These fractions contained complexes existing primarily of trimers and tetramers. The fractions from gradients containing rabbit complexes were arbitrarily divided into three regions, designated heavy, medium, and light ( Fig. 1 ), which were composed of complexes of the following size, respectively, Ab6-7:Ag3-4, Ab4-6:Ag2-3, and Ab3-4:Agl-2. These values were derived from the antibody:antigen ratio of 2, observed when both components were radioactively labeled and from molecular weight markers on a simultaneously run gradient. The respective size fractions were pooled and usually diluted 1:1 before injection. Complexes were used only on the day of preparation to avoid further aggregation, which we had observed when complexes were allowed to stand for several days.
Since immune complexes were prepared at a point where not all antibodies were combined with antigen, it was necessary to establish that both OR and ASOR were interacting with the same antibodies. To do this, we tested the ability of each to inhibit precipitation by the other. To a constant quantity of purified antibody solution we added enough OR or an identical quantity of ASOR to yield a precipitate after overnight incubation. Simultaneously, either a 10-fold excess of the homologous or heterologous antigen, or buffer was added. The degree of inhibition of precipitation was measured by comparing precipitates in the presence of buffer and in the presence of excess antigen. The ability of the two antigens to inhibit precipitation was independent of the precipitating antigen used. This established that both antigens reacted equally well with the same antibody molecules, not merely with some ofthe molecules in the purified preparation. Furthermore, analogous experiments, in which a 10-fold excess of the same or the other antigen was added to mixtures before density gradient centrifugation, showed that a reduction in the size of complexes from heavy oligomers to dimer and monomer could be accomplished equally well with an excess of either antigen in the presence of the other. To prove that both ASOR and OR could react with the same goat antibody molecules, an affinity column of the purified goat antibodies was made. Unlabeled ASOR and OR passed over the column were able indistinguishably to inhibit the binding of radiolabeled ASOR.
Complexes with either intact ceruloplasmin or asialo-ceruloplasmin were made by mixing radioiodinated antibody at twofold antigen excess of equivalence (as determined of a quantitative precipitin test) with either ceruloplasmin or asialo-ceruloplasmin. After a 30-min incubation at room temperature, the complexes were separated into heavy, medium, and light weight fractions over a sucrose density gradient, as described above for the rabbit anti-OR complexes. The complexes were used on the day of preparation and diluted 1:1 before intravenous injection.
In vivo blood clearances. 1-3 ,ug of the radiolabeled antibody-antigen complex or antigen alone in a volume of no more than 0.3 ml was injected via the tail vein into 20-g C3H female mice. Starting at 1 min, blood samples were obtained over 30-60 min from the retroorbital sinus using a 25-,ul calibrated micropipette (Clay-Adams Inc., Parsippany, N. Y.). The blood samples were then expelled into 1.5-ml plastic microfuge tubes and assayed for radioactivity with a Beckman Gamma 8000 spectrophotometer (Beckman Instruments). The clearance curves for the complexes are presented as percentage of 1251 radioactivity (antibody-associated radioactivity) remaining in the blood, the 1-min sample serving as zero time and 100%. For antigen alone, the trichloroacetic acid-precipitable radioactivity was used to generate the clearance curve.
In vivo uptake of immune complexes by the liver. A known amount of the radiolabeled immune complex was injected as described above. Either 1 h after injection (goat-OR, goat-ASOR, and rabbit-OR complexes) or 30 min after injection (rabbit-ASOR complexes), the animal was killed by cervical dislocation, and the amount of the radioactivity within the liver determined. The contaminating blood volume of the liver of a representative group of animals given complexes in various sucrose concentrations was determined using 5'Cr-labeled autologous erythrocytes as a marker of blood volume (21) . The radioactivity due to blood within the liver (always < 10%) was substracted from the total radioactivity in the liver to give a corrected value for the amount of immune complexes bound within the liver. The amount of 125I within the liver is expressed as a percentage of the total amount injected. Less than 1% of the injected radioactivity was found within the spleen and kidneys.
Inhibition studies. 15 min before injection of a tracer dose of radiolabeled immune complexes, 2-3 mg of the inhibitor was injected via the tail vein. After the injection ofthe immune complexes, serial blood samples were obtained as described. After the last sample the animal was killed, and the amount of radioactivity within the liver measured as described above. Since the inhibitors with galactose-receptor blocking activity have different numbers of terminal galactose residues capable of binding to the receptor, the same degree of inhibition of clearance or hepatic uptake per milligram of inhibitor injected should not be expected (16) . The data are presented as a percentage of injected radioactivity within the liver and as the percentage of suppression of uptake induced by the inhibitor.
Autoradiography. OR and ASOR complexes made with rabbit antibodies were made as described above and were injected into the animal without prior separation on the sucrose density gradient. This was done to prevent the vacuolization of hepatocytes that occurs after the injection of sucrose. Since a negligible amount of uncomplexed antibody is found in the liver after intravenous injection (21), the autoradiographs reflect the uptake of complexes. Enough material was injected to allow for 105 cpm to be taken up into the liver. The animal was killed and the liver placed in 10% formalin. 5-,um sections were prepared and deparafinized. The deparafinized sections were dipped into NTB-2 Nuclear Tract Emulsion (Eastman Kodak Co., Rochester, N. Y.) and allowed to remain for 10 d at 4°C. The slides were then developed with D19 (Kodak), fixed with Rapid fixer (Kodak), and stained lightly with hematoxalin and eosin.
Liver cell separation studies. A modification of the method of Steer et al. (24) was used for the isolation and purification of mouse hepatocytes and nonparenchymal cells. Mice were anesthetized with 20 mg sodium pentobarbital i.p. After laparotomy the portal vein was isolated and cannulated with a 22-gauge Angiocath (Deseret Pharmaceuticals, Sandy, Utah), which was passed to the porta hepatis. The inferior vena cava was then cannulated with a 22-gauge Angiocath. The liver was flushed via the portal vein with 2 ml of warmed, oxygenated Krebs-Henseleit buffer without calcium, pH 7.4, and then connected to a perfusion apparatus as described by Krebs et al. (25) . The gas phase was maintained at 95% 02:5% C02. The perfusate, which contained warmed Krebs- Henseleit buffer without calcium, pH 7.4 and collagenase IV (Sigma Chemical Co.) at a final concentration of 0.03% (wt/ vol), was maintained at a flow rate of 3 ml/min.
After 10 min of perfusion the liver was excised, cut into small pieces, and placed in 40 ml of Krebs-Henseleit buffer, pH 7.4, containing 2.5 mM calcium. After 2 min the liver was pressed through a 40-gauge mesh filter with the barrel of a plastic syringe (Monoject, Sherwood, Medical Industries, Inc. Deland, Fla.) and then refiltered fouir times. All fuirther operations were carried out at 4°C. The cell suspension was sedimented at unit gravity for 10 min. The resulting sediment, which contained primarily hepatocytes and cellular debris, was resuspended and washed three times in Krebs-Henseleit buffer containing 2.5% bovine serum albumin (wt/vol) after centrifugation at 50 g for 3 min, and was then resuspended in 20 ml of fresh Waymouth's medium 752/L containing 17.5%
(vol/vol) heat-inactivated newborn calf serum. The supernate, which contained primarily nonparenchymal cells, was layered gently over 16% (wt/vol) Metrizamide (Sigma Chemical Co.), pH 7.6, containing 0.24% Hepes, 0.05% KCI, and 0.018% CaCl:2H20 and centrifuged at 3,000 g for 45 min. The purified nonparenchymal cells, containing primarily Kupffer and endothelial cells, were recovered from the Metrizamide supernatant interface. These cells were washed three times in Krebs-Henseleit buffer, pH 7.4, and then resuspended in Earle's minimal essential media and 17.5% newborn calf serum. Cells were counted using a hemocytometer.
Total recovery ranged from 2 to 5 x 101 hepatocytes (20-50%) (25, 26) .
RESULTS
In vivo clearance and hepatic uptake of antigen and ofgoat immune complexes. ASOR, when injected alone intravenously, has a t1/2 in the circulation of <3 min, in contrast to OR which has a tl/2 of >1 h (Fig. 2) concentration. The injected complexes were composed of three to four antibody molecules and two to three antigen molecules. ASOR complexes were cleared much more rapidly than OR complexes (Fig. 3 ). 1 h after injection 10% of the OR complexes were within the liver, whereas 37% of the ASOR complexes were in the liver at that time (Fig. 3) . Because complexing of OR with goat antibody did not markedly alter its rate of clearance, whereas, once complexed with antibody, ASOR was removed from the circulation somewhat more slowly (Fig. 3) , the differences observed in the clearance curves for OR and ASOR immune complexes (Fig. 3 ) therefore predominantly resulted from the differences in the structure between the two antigens; that is, the exposure of a penultimate galactose on ASOR. (Although the radiolabel followed in Fig. 3 was within the antibody, the clearance curves were similar when the radiolabel followed was within the antigen.) Because ASOR complexed with antibody remained circulating longer than in an uncomplexed state, this might enhance the antigenicity of ASOR, thereby possibly enabling more immune complexes to form.
A blocking dose of uncomplexed ASOR (2 mg) markedly suppressed the in vivo clearance and hepatic uptake ofthe ASOR complex ( Figs. 3 and 4 ; Table I ). In contrast, the rapid clearance and hepatic uptake of the ASOR complex was essentially unaffected by a prior injection of human heat-aggregated gamma globulin (HAG) in a dose known to block 60-75% of the available Fc receptors in the liver (5) (Fig. 4 (27) , we studied the behavior of complexes prepared with purified rabbit anti-OR. Mouse liver reticuloendothelial cells have been shown to recognize rabbit immunoglobulin in immune complexes (21) . We prepared complexes from purified rabbit antibodies radiolabeled with 1251 and either OR or ASOR (each either unlabeled or 13I-labeled) and studied the behavior of light (3-4 Ab:1-2 Ag), medium (4-6 Ab:2-3 Ag), and heavy (6-7 Ab:3-4 Ag) complexes. The clearance curves and hepatic uptake data are presented using 1251 radioactivity. If the antigen label (1311) was followed instead of antibody (1251), the results were similar.
Whereas light OR complexes were cleared poorly from the circulation, resembling the poor clearance described for other small immune complexes in mice, light ASOR complexes were removed rapidly (Fig. 5) .
Htuman HAG, an Fc receptor blocking agent, had no effect on the clearance of the light ASOR complex, whereas a large dose of ASOR markedly inhibited its clearance (Fig. 5) . The hepatic uptake of the ASOR complex was 80% stuppressed by the blocking dose of ASOR, whereas aggregated gamma globulin had only a minimal effect (Table IIA) .
Medium OR complexes were cleared f:aster than light OR complexes and more were found within the liver at 1 h after injection (Table IIB) . Furthermore, the clearance and hepatic uiptake of the OR complexes could be markedly suppressed by a prior injection of HAG, which indicates that this clearance was probably Fc receptor mediated (Table IIB) . With medium ASOR complexes uptake was similarly accelerated, but there was evidence that both galactose and Fc receptors were involved. Aggregated gamma globulin caused a 35% reduction in hepatic localization of the ASOR complex, and ASOR caused a 62% reduction, which suggests that about two-thirds of the complexes were cleared via the galactose receptor and one-third via an Fc receptor. Galactose-substituted Ficoll also inhibited the hepatic uiptake of the complex.
As the size of the complexes increased, the Fc portion of the antibody had a greater influence on the behavior of the complex. About 55% of heavy rabbit OR complexes remained in the circulation at 1 h. As expected, aggregated gamma globulin markedly inhibited this clearance (Fig. 6 and Table IIC) . A prior injection of ASOR also diminished the amount of complex within the liver, but this was probably duie to a reduction in complex size by antigen excess, because asialofetuin and asialo-ceruloplasmini, both blockers of galactosemediated uiptake, had very little effect on the clearance and hepatic uiptake of these OR complexes.
The heavy ASOR complexes demonstrated rapid in vivo clearance, with only 30% of the complexes remaining in the blood at 30 min. As with the medium weight ASOR complexes, the fate of the heavy ASOR complexes was influenced to a large extent by a prior injection of aggregated gamma globulin. This led to a flattening of the clearance curve and to a 39% decrease in the uptake of these complexes by the liver. Moreover, ASOR markedly inhibited the clearance and uiptake of the ASOR complexes, probably by blocking galactose receptors on hepatocytes as well as by establishing a state of antigen excess that would result in smaller complexes. Even if a blocking dose of ASOR decreased the size of the complexes from heavy to light, however, the hepatic uptake of the resulting complexes was still less than the uptake of light weight ASOR complexes (38 vs . 62%, Table II ). This decrease in uptake is most consistent only with the blocking of galactose receptors by ASOR, which would thus pre- vent uptake. The unrelated antigens asialofetuin and asialo-ceruloplasmin, which would have no effect on the size of the complexes, had intermediate inhibitory effects on the in vivo fate of the ASOR complexes (Fig.  6) . Thus it appears that although half of the heavy complexes were removed from the serum by binding to Fc receptors, the other half were removed by binding to galactose receptors. Immune clearance and hepatic uptake of ceruloplasmin complexes. Soluble complexes made with rabbit antiasialo-ceruloplasmin and either intact ceruloplasmin or asialo-ceruloplasmin behaved similarly to the rabbit OR and ASOR complexes. All three sizes of the asialo-ceruloplasmin complexes were cleared more, rapidly than the complexes of the same size containing intact ceruloplasmin. This difference was most clearly apparent with the light complexes. At 20 min after injection, 79% of the ceruloplasmin complexes remained in the circulation, compared with only 44% of the asialo-ceruloplasmin complexes. Correspondingly, 30% of the injected ceruloplasmin complexes were found within the liver at 30 min, whereas with the asialo-ceruloplasmin complexes this value was 64%. A prior injection of ASOR (which had no effect on complex size) in a dose sufficient to block most of the galactose receptors reduced the hepatic uptake of the light asialo-ceruloplasmin complexes from 64 to 30%; it had a negligible effect on the disposition of heavy ceruloplasmin complexes.
Autoradiography. After injection of radioactive rabbit OR complexes, the localization of the complexes within the liver is primarily within the sinusoidal cells (Fig. 7A, arrows) , which implies that these complexes are removed from the circulation preferentially by Fc receptors. In contrast, rabbit ASOR complexes show both sinusoidal and hepatocyte localization (Fig. 7B) It seems probable that antigens other than those we tested can bind to cells via terminal sugars or indeed other structural features and thereby lead to the binding of complexed immunoglobulins to receptor-bearing tissues. Since it appears that there is a definite period of time after an immuine complex has bound onto a cell surface and before it has been internalized (30), these complexes might be able to fix comiiplement and thus initiate a series of events that might result in localized inflammation. This process would appear to be capable of subverting a major goal of the immune system, the orderly disposal of foreign substances.
There are several ways an immune complex might deposit in the tissue independent of Fc receptors. Small complexes consisting of dimers and trimers of IgG are not readily removed by the reticuloendothelial system, presumably because of inadequate aggregation of the Fc pieces. Larger complexes (4-6 IgG molecules) are rapidly removed. Since the small complexes also fix complemeint poorly, it seems that if tissue injury is to occur via these complexes, ways must exist for them to bind to cell surfaces, where their effector function would be more efficient (31) . One way miglht be by passive diffuisioni, b1ut this would not explain the diversity of tissues involved in complex-mediated injury. A second way is that the charge characteristics of the complex could cause it to bind preferentially in some locations. This has been demonstrated using as antigens proteins to which haptens have been conjugated (32, 33) and using cationic antigens that bind to the anionic glomerular basement membrane (34) . A recently described third way postulates that the carbohydrate on the immunoglobulin itself influences where the complex will bind (35, 36) . A fourth way, which seems more specific, is that the antigen might lead to complex deposition at sites with receptors specific for the antigen itself.
In only a few of the immune complex-mediated diseases is the antigen known, and in even fewer is it well defined. The diseases most amenable to study are those caused by microorganisms. It is known, for example, that certain types of malaria may be complicated by an immune complex-mediated glomerulonephritis (37) , and that in chronic schistosomiasis high levels of circulating immune complexes are found (38, 39) . Antigens released from these organisms are probably of cell membrane origin and therefore probably have numerous carbohydrate chains that might be recognized by certain cells. Excreted factors from Leishmania donovani that are known to be antigenic have a glycoprotein structure that reacts with concanavalin A, which suggests mannose moieties available for binding to receptors (40, 41) . In addition, many bacterial cell walls are known to be compounds of peptidoglycan with exposed sugar side chains (42) . These antigens in an immune complex might be able to direct that complex to tissues where they could bind to specific receptors. The aggregated Fc pieces of the tissue-bound complex might then initiate an inflammatory response.
In addition to being capable of directing coomplexed immunoglobulin to a certain tissue, sugars on an antigen may influience how it is processed after binding. Since receptors exist on mononuclear phagocytic cells for the terminal sugar on glycoproteins (mannose or Nacetyl-glucosamine) and for the Fc piece of IgG, IgG complexed with antigen may be handled differently by the cell depending on which receptor recognizes it. For instance, it is known that the polysaccharide of Schistosoma nmansoni eggs localize within macrophages and persists within the cell for extended periods of time (43) . It is conceivable that the fate of this antigen might be different if it were taken up into a macrophage by a sugar receptor instead of as an immune complex via an Fe receptor. One route may be degratory, another inmmunogenic.
Fturthermore, it is known that immuiltne complexes can modulate an antibody response to the antigen within the complex (44) ; that this modulation may involve T cells; that T cells can bind concanavalin A, which suggests that mannose residues are exposed on their outer surfaces (45) ; and that some macrophages have mannose receptors (14) . It is reasonable to speculate, therefore, that if carbohydrate-containing antigens interact with macrophage receptors, they may alter macrophage-T cell interaction and hence immune responses (46) .
Finally, since there are diseases in which circulating immune complexes appear to have a pathogenetic role and diseases in which they do not, it is probable that complexes can be either destructive or neutral. In this context, we propose that the antigen may in part determine the character of a complex.
